+

WO2016011347A1 - Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse - Google Patents

Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse Download PDF

Info

Publication number
WO2016011347A1
WO2016011347A1 PCT/US2015/040901 US2015040901W WO2016011347A1 WO 2016011347 A1 WO2016011347 A1 WO 2016011347A1 US 2015040901 W US2015040901 W US 2015040901W WO 2016011347 A1 WO2016011347 A1 WO 2016011347A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cells
dendritic cell
antigen
vaccine
Prior art date
Application number
PCT/US2015/040901
Other languages
English (en)
Inventor
Brian J. Czerniecki
Gary K. Koski
Original Assignee
The Trustees Of The University Of Pennsylvania
Kent State Universty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Kent State Universty filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2016011347A1 publication Critical patent/WO2016011347A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Definitions

  • the antigen is a tumor antigen.
  • Figure 1 is a chart showing the viability and yield of cryopreserved DC 1. Recovery of cells was on average 89% and viability was 95% when cells were directly thawed and counted.
  • FIG. 6A SK-BR-3 breast cancer line was incubated with 10 ng/ml TNF-a and 100 U/ml IFN- ⁇ for 5 days, cultured for 2 more passages in absence of cytokines and then stained for SA- -galactosidase (SA- -gal) expression (senescence marker) and compared to untreated control cells. Only paired cytokines induced senescence. Top panel, representative data from 1 of 3 independent experiments. Bottom panel, densitometric analysis.
  • IFNGR and TNFR are expressed in similar levels in breast cell lines independently from their HER2 level. IFNGR, TNFR and HER2 expression in immortalized MCF-IOA mammary epithelial cells and breast cancer cell lines (SK-BR-3, BT-474, MCF-7, T-47D and MDA-MB-231) as determined by Western blot. Vinculin was used as loading control. Similar results were observed in 3 independent experiments.
  • Figure 13 Combined HER2 and HER3 blockage expression enhances Thl cytokines TNF-a and IFN- ⁇ senescence induction in MCF-7 breast cancer cells.
  • Figure 13 A SA- -gal staining was performed in MCF-7 cells transfected with non-target (NT), HER2, HER3 or a combination of HER2 and HER3 siRNA, and then treated with the concentrations listed of TNF-a and IFN- ⁇ for 5 days and cultured for 2 more passages in absence of cytokines.
  • Right panel representative data from 1 of 3 independent experiments.
  • Figure 13B representative data from 1 of 3 independent experiments.
  • the treatment regimen of the invention is used prior to receiving the other anti-cancer therapy. In another embodiment, the treatment regimen of the invention is used concurrently with receiving the other anti-cancer therapy. In another embodiment, the treatment regimen of the invention is used after receiving the other anticancer therapy.
  • the antigen-loaded APC can also be generated by introducing a polynucleotide encoding an antigen into the cell.
  • autologous is meant to refer to any material derived from the same individual to which it is later to be re-introduced into the individual.
  • B cell as used herein is defined as a cell derived from the bone marrow and/or spleen. B cells can develop into plasma cells which produce antibodies.
  • a "recombinant cell” is a host cell that comprises a recombinant polynucleotide.
  • sample or “biological sample” as used herein means a biological material from a subject, including but is not limited to organ, tissue, exosome, blood, plasma, saliva, urine and other body fluid.
  • a sample can be any source of material obtained from a subject.
  • Signal 2 as used herein generally refers to the second signal provided by DCs to T cells.
  • Signal 2 is provided by "costimulatory" molecules on the activated DC, usually CD80 and/or CD86 (although there are other co-stimulatory molecules known), and is sensed by the T cell through the surface receptor CD28.
  • Signal 3 as used herein generally refers to the signal generated from soluble proteins (usually cytokines) produced by the activated DC. These are sensed through receptors on the T lymphocyte. The 3 rd signal instructs the T cell as to which phenotypical or functional features they should acquire to best deal with the current threat.
  • T-helper indicates a sub- group of lymphocytes (a type of white blood cell or leukocyte) including different cell types identifiable by a skilled person.
  • T-helper cell according to the present disclosure include effector Th cells (such as Thl, Th2 and Thl7). These Th cells secrete cytokines, proteins or peptides that stimulate or interact with other leukocytes.
  • Transfection of an APC with an mRNA provides an advantage over other antigen- loading techniques for generating a pulsed APC.
  • the ability to amplify RNA from a microscopic amount of tissue, i.e. tumor tissue extends the use of the APC for vaccination to a large number of patients.
  • the antigenic composition must induce an immune response to the antigen in a cell, tissue or mammal (e.g., a human).
  • Togaviridae e.g. equine encephalitis viruses, rubella viruses
  • Flaviridae e.g. dengue viruses, encephalitis viruses, yellow fever viruses
  • Coronaviridae e.g. coronaviruses
  • Rhabdoviridae e.g. vesicular stomatitis viruses, rabies viruses
  • Filoviridae e.g. ebola viruses
  • Paramyxoviridae e.g. parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus
  • Orthomyxoviridae e.g. influenza viruses
  • Bungaviridae e.g.
  • Preneoplastic or hyperplastic states that may be treated or prevented using the pharmaceutical composition of the present invention (transduced DCs, expression vector, expression construct, etc.) of the present invention include but are not limited to preneoplastic or hyperplastic states such as colon polyps, Crohn's disease, ulcerative colitis, breast lesions and the like.
  • peripheral blood monocytes are obtained from a patient by combined leukapheresis and elutriation.
  • the monocytes can be cultured in SFM with GM-CSF and IL-4 overnight.
  • immature DCs can be pulsed with antigen, followed by contacting the DCs with IFN- ⁇ and LPS.
  • the activated DCs can then be suspended in a freezing medium and frozen until ready for use in
  • the present invention provides a method of treating breast cancer that is negative for ER in a subject. In some embodiments, the present invention provides a method of treating breast cancer that is negative for ER and positive for HER2 in a subject. In some embodiments, the breast cancer is a metastatic breast cancer. In some embodiments, the breast cancer is at stage I, stage II, or stage III.
  • Anti-metabolites prevent incorporation of bases into DNA during the synthesis (S) phase of the cell cycle, prohibiting normal development and division.
  • Non- limiting examples of antimetabolites include drugs such as 5-fluorouracil, 6- mercaptopurine, capecitabine, cytosine arabinoside, floxuridine, fludarabine,
  • Tamoxifen is a non-limiting example of a hormonal agent that interferes with the activity of estrogen, which promotes the growth of breast cancer cells.
  • caspase is caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, caspase-14, or a combination thereof.
  • Freshly elutriated myeloid monocytes were cultured in 6 well microplates (12xl0 6 cells/well). Culture medium consisted of Serum Free Medium ( SFM Invitrogen Carlsbad CA). The final concentration of added GMCSF was 50ng/ml and of IL4 is 1000 U/ml. Cells were cultured overnight at 37° C in 5% CO2. In some batches, the cells were pulsed with the adequate peptides after 16-20 hr and cultured for additional 6-8 hr, after which lOOOU/ml IFN- ⁇ was added. Dendritic cells were matured with TLR agonist LPS (TLR 4, lOng/ml) or R848 (TLR8, ⁇ g/ml). The maturation time was at least about 6hr. After that, the TLR agonist-activated DCs were ready for cryopreservation or immediate use.
  • TLR agonist LPS TLR 4, lOng/ml
  • R848 TLR8, ⁇ g/ml
  • DCs were harvested by gentle scraping. All medium and the cells were kept at wet ice at all times. Cells were gently washed by centrifugation at about 800RPM for 10 min. Cells (e.g., 10 xlO 6 cells) were cryopreserved in freezing medium of plasmalyte 55%, human serum albumin 40% with 5% DMSO and stored in liquid nitrogen. The results of the experiments presented herein are now described. multi-dose DC 1 vaccines
  • the multi-dose syringe ready pack DC1 vaccines can be used to treat autoimmune diseases. Diseases like rheumatoid arthritis and Lupus occur when the immune system mistakenly attacks the body's own normal tissues.
  • the current vaccine/immunotherapy formulation is designed to initiate and strengthen immune responses, without wishing to be bound by any particular theory, it is believed that in vitro signals can be provided to the DCs during vaccine production that induce these cells to switch off pathological immune responses.
  • Example 2 Cryopreservation of Activated DC1 Makes Large Scale Dendritic Cell Vaccines Feasible in Cancer Therapy
  • Dendritic cell-based vaccine therapy is a promising directed therapy against a variety of cancers. While a variety of strategies have been employed to mature DCs to a phenotype that optimizes sensitization of CD4+ and CD8+ T cells to recognize tumor epitopes and elicit antitumor immunity, experiments were designed to utilize a method that employs the rapid maturation of monocytes in serum free media (SFM) using Interferon gamma (IFN- ⁇ ) and lipopolysaccharide (LPS), a toll-like receptor (TLR) 4 agonist, resulting in mature DCs capable of polarizing the immune response to a Thl- type response and eliciting sensitization via an IL-12 dependent mechanism. Results demonstrate the potential for this vaccine strategy to be used as an adjunct therapy in early breast cancer. Cryopreservation of dendritic cells (DCs) in a matured state permits easier production of and accessibility to personalized therapy.
  • DCs dendritic cells
  • this neoadjuvant (before surgery) strategy may eliminate the need for toxic chemotherapies for the treatment of breast cancer and therefore make immune therapy the standard of care for this disease. That is, the treatment regimen disclosed herein provides a step forwards the quest to eradicate breast cancer using the natural immune response, which can be restored with vaccines regimens of the invention.
  • the regiments discussed herein can drive immune cells into the tumor by changing the immune response in the tumor and enable the immune cells to work longer by taking the brakes off the cells. It is believed that combining DCl vaccines with Herceptin and also adding the chemokine modulator improves the migration and activity of the immune cells within the tumor in the breast.
  • 0.5xl0 5 cells were incubated in the presence of DC/CD4 + T-cell co-culture supernatants for 5 days at 37°C. In both approaches, cells were then cultured for 2 more passages in absence of cytokines and subjected to senescence studies (SA- -gal activity at pH 6 and pl5INK4b and pl6INK4a western blot) or apoptosis studies (cleaved caspase-3 western blot).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)

Abstract

La présente invention concerne un vaccin à base de cellules dendritiques (CD) par pulsation d'antigène multi-dose injectable approuvé par la FDA. Dans un mode de réalisation, le vaccin à base de CD chargé d'antigène activé comprend une dose d'immunisation initiale et plusieurs doses de rappel. L'invention concerne également un procédé permettant de bloquer HER-2 et HER-3 en tant que traitement en provoquant une sénescence de tumeur permanente dans des cancers du sein exprimant HER-2.
PCT/US2015/040901 2014-07-17 2015-07-17 Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse WO2016011347A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462025673P 2014-07-17 2014-07-17
US201462025685P 2014-07-17 2014-07-17
US62/025,685 2014-07-17
US62/025,673 2014-07-17
US201462029774P 2014-07-28 2014-07-28
US62/029,774 2014-07-28
US201562165445P 2015-05-22 2015-05-22
US62/165,445 2015-05-22

Publications (1)

Publication Number Publication Date
WO2016011347A1 true WO2016011347A1 (fr) 2016-01-21

Family

ID=55079083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/040901 WO2016011347A1 (fr) 2014-07-17 2015-07-17 Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse

Country Status (4)

Country Link
EP (2) EP3169774A4 (fr)
JP (2) JP6967963B2 (fr)
CN (1) CN107109365A (fr)
WO (1) WO2016011347A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302539A4 (fr) * 2015-05-22 2018-12-19 Brian J. Czerniecki Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques
US10973826B2 (en) 2015-10-29 2021-04-13 Novartis Ag Antibody conjugates comprising toll-like receptor agonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
WO2010124498A1 (fr) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd Cellule-souche tumorale dont la résistance a été criblée, sa composition antigénique, le chargement de cellules dendritiques antitumorales avec lesdits antigènes, leurs méthodes de préparation, utilisations et kits ainsi qu'un vaccin à base de cellules dendritiques
US20110182937A1 (en) * 2010-01-22 2011-07-28 Baylor Research Institute Dendritic Cell Vaccines
US20120156232A1 (en) * 2006-09-28 2012-06-21 Yu John S Cancer vaccines and vaccination methods
WO2013059778A2 (fr) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Vaccin anticancéreux présentant un antigène avec un interféron gamma
US20130115245A1 (en) * 2011-11-09 2013-05-09 Werner Lubitz Vaccine for Tumor Immunotherapy
WO2014090795A1 (fr) * 2012-12-11 2014-06-19 Dcprime B.V. Vaccins thérapeutiques contre le cancer dérivés d'une nouvelle lignée de cellules dendritiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
US20120237535A1 (en) * 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases
EP2542670A2 (fr) * 2010-03-05 2013-01-09 President and Fellows of Harvard College Compositions de cellules dendritiques induites et utilisations associées
AU2011227447B2 (en) * 2010-03-15 2016-04-14 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
US20120156232A1 (en) * 2006-09-28 2012-06-21 Yu John S Cancer vaccines and vaccination methods
WO2010124498A1 (fr) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd Cellule-souche tumorale dont la résistance a été criblée, sa composition antigénique, le chargement de cellules dendritiques antitumorales avec lesdits antigènes, leurs méthodes de préparation, utilisations et kits ainsi qu'un vaccin à base de cellules dendritiques
US20110182937A1 (en) * 2010-01-22 2011-07-28 Baylor Research Institute Dendritic Cell Vaccines
WO2013059778A2 (fr) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Vaccin anticancéreux présentant un antigène avec un interféron gamma
US20130115245A1 (en) * 2011-11-09 2013-05-09 Werner Lubitz Vaccine for Tumor Immunotherapy
WO2014090795A1 (fr) * 2012-12-11 2014-06-19 Dcprime B.V. Vaccins thérapeutiques contre le cancer dérivés d'une nouvelle lignée de cellules dendritiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMADA ET AL.: "Interferon-gamma up-regulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-gamma inducible protein-10 in human bladder cancer cell line RT4.", J UROL., vol. 174, no. 3, 2005, pages 1119 - 23, XP025377918, DOI: doi:10.1097/01.ju.0000168619.25341.96 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302539A4 (fr) * 2015-05-22 2018-12-19 Brian J. Czerniecki Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques
US10973826B2 (en) 2015-10-29 2021-04-13 Novartis Ag Antibody conjugates comprising toll-like receptor agonist

Also Published As

Publication number Publication date
JP2020169178A (ja) 2020-10-15
JP2017522328A (ja) 2017-08-10
EP3169774A4 (fr) 2018-04-25
EP3714898A1 (fr) 2020-09-30
JP6967963B2 (ja) 2021-11-17
EP3169774A2 (fr) 2017-05-24
CN107109365A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
US20170216421A1 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking her2 and her3, and estrogen receptor positive her2 breast receptor positive her2 breast cancer therapy
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
Schreibelt et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
US12123003B2 (en) Synthetic RIG-I-like receptor agonists
JP2022092001A (ja) 樹状細胞免疫療法
JP2020180139A (ja) 複数用量注射準備済樹状細胞ワクチンの製造
CN102933228A (zh) 制备和储存活化的、成熟树突细胞的体系和方法
US12201651B2 (en) Silicified immunogenic cells, methods of making, and methods of using
JP2018100243A (ja) テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法
Dehghan-Manshadi et al. Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer
US12150982B2 (en) Formulations of PBMCs
JP2020169178A (ja) 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
Pordanjani et al. Extracellular vesicles in vaccine development and therapeutic approaches for viral diseases
AU2019203111B2 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking HER2 and HER3, and estrogen receptor positive HER2 breast cancer therapy
US20220401535A1 (en) Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
Liu et al. Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces antigen-specific CTL responses through cDC1-mediated cross-priming mainly regulated by type I IFN signaling in mice
RU2799784C2 (ru) Способы лечения заболеваний, ассоциированных с впч
Commins Using low molecular weight substances to manipulate the innate immune response Manipulation of innate immune response with viral RNA & DNA
JP2024503278A (ja) 修飾ｐｂｍｃを用いたがんの治療方法
JP2023535981A (ja) 有核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15821911

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15821911

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载